Purimox® Compacted for DC (amoxicillin trihydrate)

Purimox® Compacted for DC (amoxicillin trihydrate)
Product Description

Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes purimox® compacted for dc (amoxicillin trihydrate). Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Granules are produced using green enzymatic technology in a sustainable and environmentally friendly manner. No solvents are used in the process leading to improved smell of the product. Application: the product is suitable for the manufacture of capsules and tablets. The product is suitable for the filling of 250 mg amoxicillin in capsule size 1. Therapeutic category: oral, broad spectrum penicillin. Shelf-life: minimum 4 years in the original packaging under 'storage conditions'. Batch size: approx. 1500- 5500 kg. Storage conditions: below 25°c, protected from light and moisture. Packaging & shipping: product is packed in 25 kg in a pe bag, which is placed inside a sealed aluminum pe bag; outer packaging is a corrugated box / hdpe drum. Contact us for more information.

Read more Show less

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Packaging; Quality Service
  • Supplied from
    Netherlands
More specifications Fewer specifications
Sales Markets
Show more Show less

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer
View company profile

More Products from Centrient Pharmaceuticals (94)

show all 94 other products

Centrient Pharmaceuticals resources (2)

  • Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    News Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

    With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

    21 Sep 2022
  • Overview Available MAs

    Technical Data Overview Available MAs

    Available Marketing Authorizations